{
    "nct_id": "NCT05552222",
    "official_title": "A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy",
    "inclusion_criteria": "* Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria\n* Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2\n* A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment\n* A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams [mg] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasone within 14 days before randomization\n* Had plasmapheresis within 28 days of randomization\n* Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization\n* Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients\n* Known contraindications to the use of daratumumab or lenalidomide per local prescribing information\n* Myeloma Frailty Index of >=2 with the exception of participants who have a score of 2 based on age alone",
    "miscellaneous_criteria": ""
}